Miami-based firm says that it is close to filing an IND for a transdermal progestogen drug delivery system for estrogen replacement therapy in postmenopausal women. The progestogen will be incorporated in Noven's interpolymeric transparent patch, which is to be worn on the lower abdomen. Noven reports discussions with several pharmaceutical companies regarding the joint development of the drug.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.